Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need.
Ratings
0 / 5
0 ratings in the last 12 months
5
4
3
2
1
CEO
Dr. Mark Erlander, PhD$105.8M
Market Cap • 25/07/20242002
(há 22 anos)
1997
(27 years ago)
NASDAQ
Listagem
San Diego
Sede • California26
N° de Empregados • 2022Valuation
Company FinancialsValuation Indicators
Valuation IndicatorsRetorno Histórico
CRDFSó no Premium...
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.